Table 2.

KM survival estimates of the various groups and subgroups in the study

(a) KM analysis showing the survival estimates of the various groups among the overall BC patients
Days from surgery to start of AC	Survival estimate at 60 months (95% CI)	Survival estimate at 90 months (95% CI)
≤ 30 days	0.871 (0.867–0.874)	0.792 (0.783–0.801)
31–60 days	0.893 (0.891–0.895)	0.812 (0.806–0.818)
61–90 days	0.882 (0.879–0.886)	0.795 (0.784–0.805)
91–120 days	0.866 (0.858–0.873)	0.777 (0.756–0.796)
> 120 days	0.844 (0.833–0.854)	0.744 (0.719–0.768)

(b) KM analysis showing the survival estimates of the various groups among TNBC patients
Days from surgery to start of AC	Survival estimate at 60 months (95% CI)	Survival estimate at 90 months (95% CI)
≤ 30 days	0.804 (0.796–0.811)	0.729 (0.710–0.747)
31–60 days	0.828 (0.822–0.833)	0.770 (0.760–0.780)
61–90 days	0.796 (0.785–0.807)	0.719 (0.696–0.741)
91–120 days	0.760 (0.736–0.782)	0.682 (0.637–0.723)
> 120 days	0.767 (0.736–0.795)	0.704 (0.656–0.746)

(c) KM survival estimates for hormone positive/HER2 negative BC patients
Days from surgery to start of AC	Survival estimate at 60 months (95% CI)	Survival estimate at 90 months (95% CI)
≤ 30 days	0.886 (0.882–0.891)	0.792 (0.778–0.804)
31–60 days	0.908 (0.905–0.911)	0.820 (0.812–0.828)
61–90 days	0.905 (0.900–0.909)	0.818 (0.805–0.830)
91–120 days	0.888 (0.878–0.897)	0.803 (0.776–0.827)
> 120 days	0.859 (0.845–0.871)	0.744 (0.706–0.778)

(d) KM survival estimates for hormone positive/HER2 positive BC patients
Days from surgery to start of AC	Survival estimate at 60 months (95% CI)	Survival estimate at 90 months (95% CI)
≤ 30 days	0.919 (0.912–0.925)	0.873 (0.857–0.887)
31–60 days	0.926 (0.921–0.930)	0.835 (0.815–0.853)
61–90 days	0.904 (0.894–0.913)	0.791 (0.753–0.823)
91–120 days	0.889 (0.870–0.905)	0.779 (0.712–0.832)
> 120 days	0.864 (0.837–0.887)	0.784 (0.737–0.823)

(e) KM survival estimates with survival comparison for BC patients who are hormone negative/HER2 positive
Groups: days from surgery to start of AC	Survival estimate at 60 months (95% CI)	Survival estimate at 90 months (95% CI)
≤ 30 days	0.885 (0.875–0.895)	0.828 (0.791–0.859)
31–60 days	0.892 (0.883–0.899)	0.824 (0.802–0.843)
61–90 days	0.854 (0.836–0.870)	0.796 (0.769–0.821)
91–120 days	0.874 (0.842–0.900)	0.770 (0.698–0.827)
> 120 days	0.848 (0.803–0.883)	0.751 (0.636–0.834)

BC breast cancer; AC adjuvant chemotherapy; ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor 2; TNBC triple negative breast cancer; KM Kaplan–Meier; CI confidence interval